How Ozempic works: separating TikTok hype from real GLP-1 science

What's this video probably claiming?

A three-minute explainer on how Ozempic works almost certainly covers the basics: semaglutide mimics a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), slows gastric emptying, signals satiety to the brain, and suppresses glucagon while stimulating insulin release in a glucose-dependent way. The creator likely explains the pancreatic angle first, then pivots to appetite suppression, possibly mentioning the hypothalamus or dopamine reward pathways. Three-minute science explainers on TikTok tend to compress mechanistic nuance into clean cause-and-effect stories, which is where accuracy problems typically begin. Expect a confident framing like "it tricks your brain into thinking you're full" or "it basically turns off hunger," both of which are oversimplifications that can mislead people evaluating whether this drug is appropriate for them.

What does the science actually show?

The GLP-1 receptor agonist mechanism is actually well-established and not particularly controversial. Semaglutide binds GLP-1 receptors in the pancreas, gut, and central nervous system. The SUSTAIN and STEP trial series confirmed dose-dependent weight loss: in STEP 1 (Wilding et al., 2021, NEJM), participants on 2.4 mg weekly semaglutide lost a mean 14.9% of body weight over 68 weeks versus 2.4% on placebo. The cardiovascular data from SELECT (Lincoff et al., 2023, NEJM) showed a 20% relative risk reduction in major adverse cardiovascular events in people with obesity but without diabetes. The gastric emptying effect is real but often overstated in duration: Nauck et al. (2011, Diabetes Care) showed that the slowing effect attenuates significantly with chronic use. The central nervous system effects, particularly on the hypothalamic arcuate nucleus and mesolimbic dopamine signaling, are supported by animal studies but remain less conclusively mapped in humans.

Where does the social media noise diverge from clinical reality?

The biggest distortion in GLP-1 TikTok content is framing semaglutide as a pure "hunger off switch" with a clean single mechanism. Real pharmacology is messier. The drug acts on at least three distinct physiological systems simultaneously, and individual response varies substantially. A second common error is conflating Ozempic (approved for type 2 diabetes at doses up to 2 mg) with Wegovy (approved for chronic weight management at 2.4 mg), as if they're interchangeable. They are not interchangeable in terms of indication or approved dosing, and any video that blurs that line creates real prescribing confusion. Compounded semaglutide products, which have flooded the market, are a separate category entirely and cannot be assumed equivalent to FDA-approved formulations. Short videos also routinely skip side effect prevalence: nausea affects roughly 44% of users in trials, and approximately 6-7% of participants in STEP trials discontinued due to GI adverse events.

What should you actually know?

Semaglutide's mechanism is real and the weight loss data are among the strongest seen in obesity pharmacotherapy in decades. But a three-minute TikTok cannot responsibly convey the clinical decision-making involved: renal dosing considerations, pancreatitis history contraindications, thyroid C-cell tumor signals from rodent studies (clinical significance in humans still unresolved), or the muscle mass loss concern raised by Bikou et al. (2024, Obesity Reviews), which found lean mass loss of roughly 25-39% of total weight lost without resistance training. If this video makes the drug sound simple, cheap, and universally appropriate, that is the red flag. Ozempic is a serious medication with a serious evidence base, not a metabolic hack. Anyone considering it deserves a real clinical conversation, not a three-minute explainer as their primary information source.